Decipher Biosciences, Inc. (DECI)
|Net Income (ttm)||-5.83M|
Decipher Biosciences, which provides genomic testing products for urologic oncology, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
Decipher Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.
Decipher Biosciences is a commercial-stage precision oncology company committed to improving patient care, with a focus in urologic oncology specific to prostate and bladder cancers. Our novel prostate cancer genomic testing products, Decipher Biopsy and Decipher RP, provide valuable information about the underlying biology of a patient’s tumor, assisting physicians in their selection of an optimal therapy. Our differentiated approach measures the biological activity of a patient’s entire tumor genome, known as whole transcriptome analysis,... [Read more...]
|IPO Date |
Tina S. Nova, Ph.D.
|Stock Exchange |
|Ticker Symbol |
In 2019, DECI's revenue was $16.52 million, an increase of 36.89% compared to the previous year's $12.07 million. Losses were -$18.45 million, -38.37% less than in 2018.